Correction to: Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia

Clin Epigenetics. 2020 Nov 18;12(1):178. doi: 10.1186/s13148-020-00964-9.

Jessica M Salmon^{1

2}, Michael Bots³, Eva Vidacs¹, Kym L Stanley¹, Peter Atadja⁴, Johannes Zuber⁵, Ricky W Johnstone^{6

7}

¹ Cancer Therapeutics Program, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, VIC, 3002, Australia.
² The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, 3010, Australia.
³ Laboratory of Clinical Chemistry, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
⁴ China Novartis Institutes for Biomedical Research, No. 2 BoYun Road, Pudong, Shanghai, 201203, China.
⁵ Research Institute of Molecular Pathology (IMP), Dr. Bohr-Gasse 7, A-1030, Vienna, Austria.
⁶ Cancer Therapeutics Program, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, VIC, 3002, Australia. ricky.johnstone@petermac.org.
⁷ The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, 3010, Australia. ricky.johnstone@petermac.org.

Abstract

An amendment to this paper has been published and can be accessed via the original article.